-
Zai Lab’s Q1 2024 Revenue Rises 43% YOY on Strong Product Launch and NRDL Inclusion
•
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the first quarter of 2024, with product revenues increasing to USD 87.1 million from USD 62.8 million in the same period of 2023, reflecting a 43% year-on-year (YOY) growth in constant exchange rate terms. The company’s research…
-
BeiGene’s Q1 2024 Revenue Jumps 68% YOY on Strength of Brukinsa and Tislelizumab Sales
•
BeiGene, Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the first quarter of 2024, revealing a total revenue of USD 752 million, marking a 68% year-on-year (YOY) increase. Product revenue specifically soared 82% YOY to USD 747 million. Notably, US sales experienced a significant surge,…
-
Organon’s Q1 2024 Revenues Rise 7% YOY, Women’s Health and Biosimilars Lead the Way
•
Organon (NYSE: OGN), a leading women’s health specialist, announced a 7% year-on-year increase in revenues for the first quarter of 2024, reaching $1.6 billion, excluding the impact of foreign exchange. This growth was primarily fueled by a robust performance in Women’s Health and Biosimilars segments, which saw revenues surge 12%…
-
Siemens Healthineers Reports 3% YOY Growth in Q2 2024 Fiscal Report Amidst Challenging Comparison
•
Germany’s medical technology leader Siemens Healthineers AG (ETR: SHL) has reported its financial results for the second quarter of fiscal 2024, which concluded on March 31, 2024. The company achieved total revenues of EUR 5.44 billion (USD 5.85 billion), marking a growth of 3% year-on-year (YOY) at constant currency. Siemens…
-
GSK’s Q1 2024 Results Beat Forecasts with 10% YOY Revenue Increase; Upgrades Full-Year Outlook
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the first quarter of 2024, with revenues increasing by 10% year-on-year (YOY) to GBP 7.4 billion (USD 9.3 billion), excluding COVID-19-related sales. Core operating profit also showed a robust performance, rising 27% YOY in constant currency terms…
-
Eli Lilly & Co. Raises Full-Year Guidance on Strength of Q1 2024 Results and Production Expansion
•
Eli Lilly & Co. (NYSE: LLY) has reported financial results for the first quarter of 2024 that exceeded expectations, with sales up 26% year-on-year (YOY) to USD 8.77 billion. The growth was driven by the strong performance of the weight-loss drug Mounjaro (tirzepatide), diabetes therapy Zepbound (tirzepatide), Jardiance (empagliflozin) for…
-
Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability
•
Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of its financial results for the first quarter of 2024. The market responded positively to the underlying portfolio growth and increased profitability, which was amplified by recent operational cost-cutting measures. Despite a challenging comparison with the…
-
Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the first quarter of 2024, reporting a 5.55% year-on-year (YOY) increase in revenues to RMB 1.373 billion (USD 190.3 million). The Chinese pharmaceutical company also saw its net profits surge by 133% YOY to RMB 155…
-
Dizal Pharmaceutical’s Sunvozertinib Logs RMB 91.29 Million in Sales Following EGFR Inhibitor Approval
•
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its next-generation epidermal growth factor receptor (EGFR) inhibitor, sunvozertinib, which received approval in August 2023 for the treatment of EGFR Exon20ins mutated non-small cell lung cancer in China, has achieved sales of RMB 91.29 million (USD…
-
WuXi AppTec’s Q1 2024 Revenues Affected by COVID-19 Project Exclusion
•
China’s leading Contract Research Organization (CRO), WuXi AppTec (HKG: 2359, SHA: 603259), has announced its financial results for the first quarter of 2024, with revenues reaching RMB 7.98 billion (USD 1.1 billion), marking a slight decrease of 1.8% year-on-year (YOY), excluding COVID-19 commercialization projects. The company’s original customer income stood…
-
Daiichi Sankyo Reports 25.3% Revenue Growth in FY2023, Boosted by Enhertu and Lixiana Sales
•
Japanese pharmaceutical company Daiichi Sankyo has reported a remarkable fiscal year 2023, with revenues increasing by 25.3% to ¥1.602 trillion (USD 10.05 billion) for the 12-month period ended March 31, 2024. The growth was primarily driven by the success of its HER2-targeted antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and…
-
RemeGen’s Q1 2024 Revenues Surge 96.41% YOY, R&D Spending Outpaces Income
•
China-based pharmaceutical company RemeGen (HKG: 9995) has reported its financial results for the first quarter of 2024, with revenues reaching RMB 330 million (USD 45.54 million) for the three-month period, marking a significant increase of 96.41% year-on-year (YOY). However, the company recorded net losses of RMB 349 million (USD 48.2…
-
Mindray Bio-Medical Electronics Reports 15.04% YOY Revenue Growth in 2023 Financial Results
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for 2023, with revenues reaching RMB 34.932 billion (USD 4.82 billion), reflecting a robust year-on-year (YOY) growth of 15.04%. Net profits for the medical equipment manufacturer surged to RMB 11.58 billion (USD 1.6 billion), marking an increase…
-
United Imaging Healthcare Reports 23.52% YOY Revenue Growth in 2023, Driven by Strong Product Launches and Partnerships
•
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has reported impressive financial results for the year 2023, with revenues reaching RMB 11.411 billion (USD 1.57 billion), marking a 23.52% year-on-year (YOY) increase. Net profits for the period were recorded at RMB 1.974 billion (USD 270 million), up 19.21% YOY. The company’s…
-
AstraZeneca Reports 19% YOY Revenue Growth in Q1 2024, Driven by Oncology and R&I
•
UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has released an impressive set of financial results for the first quarter of 2024, with overall revenues increasing by 19% year-on-year (YOY) in constant currency terms to USD 12.68 billion. Product sales soared 18% YOY, reaching USD 12.18 billion. The company’s business units…
-
Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023
•
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its first commercial sales with revenues of RMB 39.3 million (USD 5.4 million). The revenues were driven by the COVID-19 vaccine SCB-2019 (CpG 1018/Alum) and the quadrivalent influenza vaccine AdimFlu-S (QIS), which were launched in China…
-
JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva
•
China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching RMB 173.9 million (USD 24 million), marking a 19.3% year-on-year (YOY) increase. The company’s research and development (R&D) expenditure for the year was RMB 413.6 million (USD 57.08 million), up 1.4% YOY. Sales expenses were…
-
MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first quarter of 2024, announcing sales of USD 15.8 billion, an increase of 11% year-on-year (YOY) excluding the impact of foreign exchange rates. The pharmaceutical division contributed USD 14.0 billion to the top line, with a…
-
Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing
•
China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with revenues amounting to RMB 76.6 million (USD 10.57 million), primarily from its core product, HuaTangNing (dorzagliatin tablets), an oral hypoglycemic agent. The revenues were generated from the sale of 251,000 boxes of the drug since…
-
Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches
•
France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter of 2024, with sales increasing by 6.7% year-on-year (YOY) in constant exchange rate terms to €10.46 billion (USD 11.23 billion). The biopharma segment experienced growth of 6.3%, with pharmaceutical sales rising by 6.4% to €7.76…
